Gilead Sciences traded at $83.01 this Friday January 20th, decreasing $0.61 or 0.73 percent since the previous trading session. Looking back, over the last four weeks, Gilead Sciences lost 2.65 percent. Over the last 12 months, its price rose by 21.16 percent. Looking ahead, we forecast Gilead Sciences to be priced at 83.39 by the end of this quarter and at 75.41 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
83.01
Daily Change
-0.73%
Yearly
21.16%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
AbbVie 149.66 0.95 0.64% 13.40%
Acorda Therapeutics 0.98 -0.01 -0.51% -47.58%
Agios Pharmaceuticals 28.16 0.78 2.85% -5.50%
ALKERMES 27.72 -0.17 -0.61% 15.50%
Alnylam Pharmaceuticals 229.65 1.09 0.48% 68.35%
Amgen 263.24 1.21 0.46% 15.60%
Biogen 285.77 5.64 2.01% 29.59%
Bluebird Bio 6.20 0.28 4.73% -14.36%
BioMarin Pharmaceutical 110.75 1.55 1.42% 30.83%
Bristol-Myers Squibb 74.13 0.40 0.54% 16.67%
Coherus Biosciences 9.02 0.28 3.20% -28.36%
Gilead Sciences 83.01 -0.61 -0.73% 21.16%
GlaxoSmithKline 1,406.80 -11.80 -0.83% -14.59%
Glaxosmithkline 35.38 -0.23 -0.65% -21.55%
Intercept Pharmaceuticals 16.12 0.70 4.54% 4.61%
Incyte Corp 83.20 -0.68 -0.81% 11.24%
J&J 168.74 -0.79 -0.47% 2.35%
Eli Lilly 346.04 -5.01 -1.43% 42.37%
Merck & Co 109.98 0.04 0.04% 37.51%
Moderna Inc 193.98 3.60 1.89% 21.18%
Neurocrine Biosciences 111.36 1.39 1.26% 48.28%
Novartis 84.48 -0.03 -0.04% 5.77%
Puma Biotechnology 4.38 0.10 2.34% 82.50%
Pfizer 45.11 0.15 0.33% -14.55%
PTC Therapeutics 47.74 1.24 2.67% 22.98%
Regeneron Pharmaceuticals 721.88 6.43 0.90% 16.17%
Sanofi 90.73 -0.52 -0.57% -0.23%
Sangamo BioSciences 3.44 0.09 2.69% -39.44%
Sarepta Therapeutics 130.22 2.42 1.89% 105.17%
Teva Pharmaceutical Industries 10.41 -0.14 -1.33% 22.33%
United Therapeutics 261.70 1.68 0.65% 30.81%
Vertex Pharmaceuticals 309.73 1.90 0.62% 35.80%

Indexes Price Day Year
US500 3973 73.76 1.89% -9.67%
USND 11140 288.17 2.66% -19.09%
USNDX 11619 323.36 2.86% -19.53%

Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that is focused on advancing medicines to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company's portfolio of products and pipeline of investigational drugs includes treatments for HIV/acquired immune deficiency syndrome (AIDS), COVID-19, liver diseases, hematology/oncology/cell therapy and other. Its products for HIV/AIDS patients include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada and Atripla. It offers Veklury to patients with COVID-19. The Company's products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Viread and Vosevi. Its products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy and Zydelig. Other products include Letairis, Ranexa and AmBisome. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. The Company operates in more than 335 countries worldwide.